Related Experiment Videos

Second-line treatment and consolidation therapies in advanced ovarian cancer

P F Conte¹, A Gadducci, C Cianci

¹Department of Oncology, Division of Medical Oncology, University of Pisa, Italy.

International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society

|August 8, 2001

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Particle Beam Re-irradiation in Oligo Recurrent Gynecological Malignancies.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026

A-BRAVE trial: a phase III randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patients.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

PREDICTIVE BRCA GENETIC TESTING IN ITALIAN PATIENTS WITH BREAST CANCER: A POSITION PAPER OF ITALIAN SCIENTIFIC SOCIETIES [Italian Association of Medical Oncology(AIOM); Italian Association of Radiotherapy and Clinical Oncology (AIRO); Italian National Association of Breast Surgeons (ANISC); Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP); Italian Society of Surgical Oncology (SICO); Italian Society of Human Genetic (SIGU); Italian Society of General Practice (SIMG); Italian Society of Medical and Interventional Radiology (SIRM)].

Cancer treatment reviews·2025

Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023

Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2023

INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line.

British journal of cancer·2023

See all related articles